Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 30

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

707

HTML

6366

Tables (1-2)

276

Sum=7349

Aug 14, 2009 (publication date) through Mar 7, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Aug 14, 2009; 15(30): 3734-3743
Published online Aug 14, 2009. doi: 10.3748/wjg.15.3734

Table 1 Differences in toxicity of the standard treatments for colorectal cancer between whites and AAs

Regimens	Toxicity
Irinotecan and oxaliplatin	FOLFIRI, FOLFOX and IROX are less toxic to AAs than Whites
Fluoropyrimidines	5-FU is less toxic to AAs than Whites
Cetuximab	Whites are more prone to hypersensitivity reactions

AAs: African Americans.

Citation: Dimou A, Syrigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs Whites: Before and after diagnosis. World J Gastroenterol 2009; 15(30): 3734-3743
URL: https://www.wjgnet.com/1007-9327/full/v15/i30/3734.htm
DOI: https://dx.doi.org/10.3748/wjg.15.3734